Back to top

Image: Bigstock

Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC

Read MoreHide Full Article

Teleflex (TFX - Free Report) recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift 2 System with ATC (UroLift 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

The recent development is also expected to significantly enhance Teleflex’s Interventional Urology product category.

More on the UroLift 2 ATC

Teleflex’s UroLift 2 System leads the market as a proven minimally invasive treatment for BPH that provides an effective alternative to BPH medications and major surgery. The UroLift 2 ATC represents a breakthrough in BPH treatment, featuring an adaptable design that enables physicians to customize treatments to each patient’s unique anatomy. This personalized approach is poised to help maximize effectiveness.

Zacks Investment Research
Image Source: Zacks Investment Research

The system offers physicians enhanced confidence, improved control of obstructive tissue and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise. A streamlined delivery system, utilizing one handle per procedure and individual implant cartridges, also ensures increased physician comfort and improves efficiency during the procedure.

News in Detail

UroLift 2 ATC is said to optimize enlarged prostate treatment by providing urologists with unparalleled confidence and customization capabilities.

According to the company’s spokesperson for The Americas, the UroLift 2 System with ATC offers a comprehensive solution for BPH care, combining cutting-edge technology with proven clinical outcomes. The innovative platform streamlines procedures and eliminates the need to transition between platforms during a procedure. Enhanced features, including greater and more consistent implant compression and reduced waste, are expected to boost healthcare delivery outcomes and efficiency.

Furthermore, the Vice President of Research and Development for Teleflex Interventional Urology underscored that the system is designed to deliver the same proven effectiveness of the UroLift System, with significant enhancements on a unified UroLift 2 platform. Based on physician feedback, the UroLift 2 ATC maintains the efficacy of the UroLift System, improves overall performance and offers physicians the advantage of efficiently treating a broader range of patients. This expanded capability opens up new avenues for patient care.

Industry Prospects

Per a Research report, the global BPH treatment devices market was valued at $1.42 billion in 2022 and is expected to witness a CAGR of 8.9% by 2030.

Developments in the Interventional Urology Portfolio

In the last reported fourth quarter of 2023, the product category registered a 4.2% increase in revenues, bolstered by the acquisition of Palette Life Sciences. Revenues modestly exceeded expectations, mainly due to the outperformance of Barrigel — the NASHA (Non-Animal Stabilized Hyaluronic Acid) spacer designed by Palette. UroLift revenues in international markets, particularly Japan, saw healthy growth, while initial launch activities in China remained on the plan, with an emphasis on training surgeons and gaining reimbursement.

In November 2023, the company highlighted the results of a new peer-reviewed study, which suggested that within a year of BPH surgery, one in 20 patients may require retreatment regardless of whether they receive a TURP (Transurethral Resection of the Prostate), GreenLight, Rezum or UroLift. Additionally, at one year, procedural complications requiring a return procedure in the outpatient setting were lowest following UroLift and highest following Rezum. The average time to the first complication was the longest for UroLift. These outcomes are said to have reinforced the position of the UroLift system as the goal standard in minimally invasive surgical treatment for BPH.

Price Performance

In the past six months, TFX shares have decreased 28.6% against the industry’s rise of 29.5%.

Zacks Rank and Key Picks

Teleflex currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are DaVita (DVA - Free Report) , Stryker (SYK - Free Report) and Cardinal Health (CAH - Free Report) . While DaVita sports a Zacks Rank #1 (Strong Buy), Stryker and Cardinal Health each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

DaVita’s stock has surged 61.5% in the past year. Earnings estimates for DaVita have risen from $8.97 to $9.23 in 2024 and from $9.77 to $10.01 in 2025 in the past 30 days.

DVA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.6%. In the last reported quarter, it posted an earnings surprise of 22.2%.

Estimates for Stryker’s 2024 earnings per share have remained constant at $11.86 in the past 30 days. Shares of the company have moved 21.8% upward in the past year compared with the industry’s rise of 2.8%.

SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%. In the last reported quarter, it delivered an average earnings surprise of 5.8%.

Estimates for Cardinal Health’s 2024 earnings per share have moved down 0.1% to $7.28 in the past seven days. Shares of the company have surged 38% in the past year compared with the industry’s 9.5% rise.

CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%. In the last reported quarter, it delivered an average earnings surprise of 16.7%.

Published in